Dose dependent inhibition of B-16 melanoma growth in vivo by a synthetic analogue of PGE2.
Daily intratumor administration of 16,16-dimethyl-PGE2-methyl ester in two different dosages inhibited tumor growth in C57Bl/6J mice bearing subcutaneous B-16 melanomas. The larger dose (20 microgram/day/mouse) produced a 68% decrease in tumor volume, a 69% decrease in tumor weight and a 60% decrease in the number of cells in mitotic phase. The smaller dose (10microgram/day/mouse) was one fifth less effective than the 20microgram dose but produced similar changes. Histological examination of tumors revealed no significant differences either in the inflammatory cell population or the amount of necrosis in the control and di-M-PGE2-treated tumors.
D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008938:Mitosis / Q000187:drug effects; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D011459:Prostaglandins E, Synthetic